Clinical trial · no report yet · Phase 3
PROOF302
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- NCT04197986 ↗
- Terminated
- QED Therapeutics, a BridgeBio company
- 26 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 6 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Upper Tract Urothelial Carcinomas; Urothelial Bladder Cancer
- Interventions
- Infigratinib; Placebo
- Arms
- Infigratinib 125 mg · Experimental
- Placebo · Placebo comparator
- Enrollment
- 39
- Primary outcomes
- Centrally Determined Disease-free Survival (DFS)
- Sponsor
- QED Therapeutics, a BridgeBio company with Helsinn Healthcare SA
- Start
- Mar 11, 2020
- Primary completion
- Feb 28, 2023
- Results posted
- Yes
- Registry record
- NCT04197986 · updated Mar 13, 2024
Publications
linked from the registry- Szymaniak J, Porten SP. Which Biomarkers are Useful in the Management of Muscle-invasive Bladder Cancer in 2022? Eur Urol Focus. 2022 Jul;8(4):901-903. doi: 10.1016/j.euf.2022.08.009. Epub 2022 Sep 2. PubMed 36058810
- Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul;18(21):2599-2614. doi: 10.2217/fon-2021-1629. Epub 2022 May 24. PubMed 35608106